Drug
Ropeginterferon alfa-2b clinical trials
Also written P1101, AOP2014 and Besremi.
Keep track of what changes. Save the ropeginterferon alfa-2b studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
34 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 4 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 14
PharmaEssentia (11) · AOP Orphan Pharmaceuticals AG (5) · National Taiwan University Hospital (5) · PharmaEssentia Japan K.K. (4) · The University of Hong Kong (2) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Ribavirin (2) · Entecavir (1) · Ruxolitinib (1) · Azacitidine (1)
Studies
Open first, then newest update. How each study uses ropeginterferon alfa-2b is read from its arms, and is right about nine times in ten.
Testing it · 34
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruitingPhase 1University of UtahNCT07521046Written as ropeginterferon alfa- 2b
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 MutationsRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07646821Written as ropeginterferon alfa- 2b
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaNot yet recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07468916Written as Ropeginterferon Alfa-2B
- Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)RecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07047885Written as Ropeginterferon alfa-2b
- Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisRecruitingPhase 2The University of Hong KongNCT06770842Written as Ropeginterferon alfa-2b (BESREMi®)
- Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsRecruitingPhase 3PharmaEssentia Japan K.K.NCT04655092Written as P1101 (Ropeginterferon alfa-2b)
- Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With ComorbiditiesNot yet recruitingPhase 2/3National Taiwan University HospitalNCT05808322Written as Ropeginterferon alfa-2b
- Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk MyelofibrosisRecruitingPhase 2National Taiwan University HospitalNCT05731245Written as Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]
- Ropeginterferon Alfa 2b for Early MyelofibrosisRecruitingPhase 2The University of Hong KongNCT04988815Written as Ropeginterferon alfa-2b
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskActive, not recruitingPhase 3PharmaEssentiaNCT06468033Written as Ropeginterferon alfa-2b
- Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia VeraWithdrawnPhase 4PharmaEssentiaNCT06290765Written as Ropeginterferon alfa-2b
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceActive, not recruitingPhase 3PharmaEssentiaNCT04285086Written as Ropeginterferon alfa-2b
- The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D InfectionCompletedPhase 1PharmaEssentiaNCT04638439Written as P1101 + Nivolumab + Entecavir
- P1101 in Treating Patients With MyelofibrosisTerminatedPhase 2Mayo ClinicNCT02370329Written as Ropeginterferon Alfa-2B
- Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to ApplyCompletedPhase 2PharmaEssentia Japan K.K.NCT04182100Written as P1101
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVActive, not recruitingPhase 3PharmaEssentiaNCT05481151Written as P1101 (Ropeginterferon alfa-2b-njft)
- A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ETActive, not recruitingPhase 2PharmaEssentiaNCT05482971Written as Ropeginterferon alfa-2b-njft (P1101)
- A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HUActive, not recruitingPhase 2PharmaEssentiaNCT05485948Written as Ropeginterferon alfa-2b
- A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia PatientsActive, not recruitingPhase 3AOP Orphan Pharmaceuticals AGNCT06514807Written as Ropeginterferon alfa-2b (BESREMi®)
- A Study to Evaluate P1101 in Japanese PV PatientsCompletedPhase 3PharmaEssentia Japan K.K.NCT06002490Written as P1101
See all 34 studies that test ropeginterferon alfa-2b →
Given in every arm · 2 — ropeginterferon alfa-2b is usual care beside what is tested
- Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseRecruitingPhase 2M.D. Anderson Cancer CenterNCT07269470Written as Ropeginterferon alfa-2b (P1101)
- A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-InfectionNot yet recruitingPhase 2National Taiwan University HospitalNCT05467553Written as Ropeginterferon alfa-2b
As the comparator · 1 — what is tested is compared with ropeginterferon alfa-2b
Codes
What other systems call ropeginterferon alfa-2b · ClinicalTrials.gg INT002159
- MeSH (NLM) C000731926ropeginterferon alfa-2bOne source NLM
- UNII (FDA) 981TME683SROPEGINTERFERON ALFA-2BConfirmed FDA, NLM, Wikidata
- RxNorm 2587059One source FDA
- Wikidata Q99754007ropeginterferon alfa-2bConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C111892Ropeginterferon Alfa-2BOne source FDA
- DrugBank DB15119One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731926 | ropeginterferon alfa-2b | One source NLM |
| UNII (FDA) | 981TME683S | ROPEGINTERFERON ALFA-2B | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2587059 | — | One source FDA |
| Wikidata | Q99754007 | ropeginterferon alfa-2b | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C111892 | Ropeginterferon Alfa-2B | One source FDA |
| DrugBank | DB15119 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.